CRO startup Vial scores $67M Series B led by General Catalyst
Vial, a CRO specializing in offering clinical trial services to biotech companies, raised $67 million in a new round of funding, bringing its total money raised to $100 million.
The San Francisco-based company’s Series B round was led by General Catalyst and supported others such as Byers Capital and BoxGroup.
Vial co-founder and CEO Simon Burns said the company will use the funding to expand its clinical operations and strategy teams in the US and across the European Union and Asia-Pacific in order to support its clients globally.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.